Cargando…

The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome

AIM: The aim of the study was to assess the effectiveness of a patented preparation of sodium butyrate in the triglyceride matrix at reducing clinical symptoms and improving quality of life in patients with irritable bowel syndrome (IBS). MATERIAL AND METHODS: In this prospective multicenter clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewandowski, Konrad, Kaniewska, Magdalena, Karłowicz, Katarzyna, Rosołowski, Mariusz, Rydzewska, Grażyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942000/ https://www.ncbi.nlm.nih.gov/pubmed/35371361 http://dx.doi.org/10.5114/pg.2021.112681

Ejemplares similares

The Use of Virtual Reality to Reduce Stress among Inflammatory Bowel Disease Patients Treated with Vedolizumab
por: Lewandowski, Konrad, et al.
Publicado: (2021)

Gastrointestinal symptoms in COVID-19
por: Lewandowski, Konrad, et al.
Publicado: (2022)

Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) – friend or foe?
por: Lewandowski, Konrad, et al.
Publicado: (2021)

Low-FODMAP Diet for the Management of Irritable Bowel Syndrome in Remission of IBD
por: Więcek, Martyna, et al.
Publicado: (2022)

Long-lasting dyspeptic symptoms – another consequence of the COVID-19 pandemic?
por: Nazarewska, Anna, et al.
Publicado: (2023)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
por: Kaniewska, Magdalena, et al.
Publicado: (2020)

Selected Aspects of Nutrition in the Prevention and Treatment of Inflammatory Bowel Disease
por: Panufnik, Paulina, et al.
Publicado: (2022)

Skin and gastrointestinal symptoms in COVID-19
por: Ciechanowicz, Piotr, et al.
Publicado: (2020)

Awareness and Compliance with the Recommendations of Primary and Secondary Prevention of Cancer in Patients with Inflammatory Bowel Disease
por: Tulewicz-Marti, Edyta, et al.
Publicado: (2023)

Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease
por: Facchin, Sonia, et al.
Publicado: (2020)

Butyric acid in irritable bowel syndrome
por: Załęski, Andrzej, et al.
Publicado: (2013)

Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything?
por: Lewandowski, Konrad, et al.
Publicado: (2023)

Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients
por: Szczubełek, Martyna, et al.
Publicado: (2021)

Reply to van Lingen et al. Comment on “Szczubełek et al. Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients. Nutrients 2021, 13, 4112”
por: Szczubełek, Martyna, et al.
Publicado: (2022)

Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of a Randomized Double-Blind Placebo-Controlled Trial
por: Gąsiorowska, Anita, et al.
Publicado: (2022)

Use of functional magnetic resonance imaging in patients with irritable bowel syndrome and functional dyspepsia
por: Skrobisz, Katarzyna, et al.
Publicado: (2019)

Bone Metabolism Alteration in Patients with Inflammatory Bowel Disease
por: Tulewicz-Marti, Edyta Maria, et al.
Publicado: (2022)

The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review
por: Daniluk, Jaroslaw, et al.
Publicado: (2022)

Butyric acid – a well-known molecule revisited
por: Borycka-Kiciak, Katarzyna, et al.
Publicado: (2017)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
por: Kaniewska, Magdalena, et al.
Publicado: (2017)

Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome
por: Pozuelo, Marta, et al.
Publicado: (2015)

Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik
por: Pietrzak, Anna, et al.
Publicado: (2018)

Management of anaemia in patients with inflammatory bowel disease – results of a questionnaire among Polish healthcare professionals
por: Tulewicz-Marti, Edyta M., et al.
Publicado: (2021)

Probiotics in irritable bowel syndrome – is the quest for the right strain over? Rapid review of existing guidelines and recommendations
por: Marlicz, Wojciech, et al.
Publicado: (2021)

The introduction of the IBD Disk in Poland – a new tool for assessing disability in patients with inflammatory bowel disease
por: Eder, Piotr, et al.
Publicado: (2019)

Determination of butyric acid dosage based on clinical and experimental studies – a literature review
por: Banasiewicz, Tomasz, et al.
Publicado: (2020)

Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study
por: Krokowicz, Lukasz, et al.
Publicado: (2013)

Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome
por: Nozu, Tsukasa, et al.
Publicado: (2019)

Iron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group Recommendations
por: Kaniewska, Magdalena, et al.
Publicado: (2014)

The Effects of Sodium Butyrate, Coated Sodium Butyrate, and Butyric Acid Glycerides on Nutrient Digestibility, Gastrointestinal Function, and Fecal Microbiota in Turkeys
por: Makowski, Zbigniew, et al.
Publicado: (2022)

Irritable bowel syndrome: Is it “irritable brain” or “irritable bowel”?
por: Padhy, Susanta Kumar, et al.
Publicado: (2015)

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
por: Vernero, Marta, et al.
Publicado: (2020)

Effect of sodium butyrate regulating IRAK1 (interleukin-1 receptor-associated kinase 1) on visceral hypersensitivity in irritable bowel syndrome and its mechanism
por: He, Yuqin, et al.
Publicado: (2021)

Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome
por: Wollny, Tomasz, et al.
Publicado: (2021)

The Impact of an Individual Educational Program on the Quality of Life and Severity of Symptoms of Patients with Irritable Bowel Syndrome
por: Sierżantowicz, Regina, et al.
Publicado: (2020)

The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
por: Tian, Zhenyi, et al.
Publicado: (2020)

Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms
por: Cui, Xiufang, et al.
Publicado: (2021)

Effectiveness of Menthacarin on symptoms of irritable bowel syndrome
por: Madisch, Ahmed, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j0j01j5hi8ptv05ecp0o114b2r